Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam

Infection and Immunity

Volumn 67, Issue 11, 1999, Pages 5806-5810

  Kossaczka, Zuzana ^a   Lin, Feng Ying C ^a   Ho, Vo̊ Anh ^b   Thuy, Nguyen Thi Thanh ^c   Van Bay, Phan ^b   Thanh, Tran Cong ^c   Khiem, Ha Ba ^c   Trach, Dang Duc ^d   Karpas, Arthur ^a   Hunt, Steven ^a   Bryla, Dolores A ^a   Schneerson, Rachel ^a   Robbins, John B ^a   Szu, Shousun C ^a  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b Huu Nghi Hospital   (Viet Nam)

^c PASTEUR INSTITUTE   (Viet Nam)

^d NATIONAL INSTITUTE OF HYGIENE AND EPIDEMIOLOGY   (Viet Nam)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN A ANTIBODY; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY; TYPHOID VACCINE;

ACTIVE IMMUNIZATION; ADOLESCENT; ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; BACTERIAL VIRULENCE; CHILD; DRUG EFFICACY; DRUG SAFETY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; IMMUNOGENICITY; IMMUNOGLOBULIN PRODUCTION; INFECTION CONTROL; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; SALMONELLA TYPHI; TYPHOID FEVER; VIET NAM;

EID: 0032708670     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.67.11.5806-5810.1999     Document Type: Article

References (38)

1. Acharya, I. L., C. U. Lowe, R. Thapa, V. L. Gurubacharya, M. B. Shrestha, D. A. Bryla, T. Cramton, B. Trollfors, M. Cadoz, D. Schulz, J. Armand, R. Schneerson, and J. B. Robbins. 1987. Prevention of typhoid fever in Nepal with the Vi capsular polysaccharide of Salmonella typhi: a preliminary report one year after immunization. N. Engl. J. Med. 317:1101-1104.
2. Bodhidatta, L., D. N. Taylor, U. Thisyakorn, and P. Echeverria. 1987. Control of typhoid fever in Bangkok, Thailand, by annual immunization of school children with parenteral typhoid vaccine. Rev. Infect. Dis. 9:841-845.
3. Brugier, J.-C., A. Barra, D. Schulz, and J.-L. Preud'homme. 1993. Isotypes of human vaccinal antibodies to the Vi capsular polysaccharide of Salmonella typhi. Int. J. Clin. Lab. Res. 23:38-41.
4. Davis, T. M. E., A. E. Makepeace, E. A. Dallimore, and K. E. Choo. 1999. Relative bradycardia is not a feature of enteric fever in children. Clin. Infect. Dis. 28:585-586.
5. Engels, E. A., M. E. Falagas, J. Lau, et al. 1998. Typhoid fever vaccines: a meta-analysis of studies on efficacy and toxidty. BMJ 316:110-116.
6. Fass, R., M. van de Walle, A. Shiloach, A. Joslyn, J. Kaufman, and J. Shiloach. 1991. Use of high density cultures of Escherichia coli for high level production of recombinant Pseudomonas aeruginosa exotoxin A. Appl. Microbiol. Biotechnol. 36:65-69.
7. Fattom, A., J. Shiloach, D. A. Bryla, D. Fitzgerald, I. Pastan, W. W. Karakawa, J. B. Robbins, and R. Schneerson. 1992. Comparative immunogenicity of conjugates composed of the Staphylococcus aureus type 8 capsular polysaccharide bound to carrier proteins by adipic acid dihydrazide or N-succinimidyl-3-(2-pyridyldithio)propionate. Infect. Immun. 60:584-589.
8. Gaines, S., J. A. Currie, and J. G. Tully. 1965. Production of incomplete Vi antibody in man by typhoid vaccine. Am. J. Epidemiol. 81:350-355.
9. Gilman, R. H., M. Terminel, M. M. Levine, P. Hernandez-Mendoza, and R. B. Hornick. 1975. Relative efficacy of blood, urine, rectal swab, bone-marrow, and rose-spot cultures for recovery of Salmonella typhi in typhoid fever. Lancet 1:1211-1213.
10. Hoa, N. T. T., T. S. Diep, J. Wain, C. M. Parry, T. T. Hien, M. D. Smith, A. L. Walsh, and N. J. White. 1998. Community-acquired septicaemia in southern Vietnam: the importance of multidrug-resistant Salmonella typhi. Trans. R. Soc. Trop. Med. Hyg. 92:503-508.
11. Hornick, R. B., S. E. Greisman, T. E. Woodward, H. L. DuPont, A. T. Dawkins, and M. J. Snyder. 1970. Typhoid fever: pathogenesis and immunologic control. II. N. Engl. J. Med. 283:739-746.
12. Ivanoff, B., M. M. Levine, and P. H. Lambert. 1994. Vaccination against typhoid fever: present status. Bull. W. H. O. 72:957-971.
13. Johansson, H. J., C. Jägersten, and J. Shiloach. 1996. Large scale recovery and purification of periplasmic protein from E. coli using expanded bed adsorption chromatography followed by new ion exchange media. J. Biotechnol. 48:9-14.
14. Kawata, Y. 1970. A study of the molecular types of immunoglobulin. II. Mouse protection study of Vi antibody against typhoid infection. Acta Sch. Med. Univ. Kioto 40:284-290.
15. Keddy, K. H., K. P. Klugman, C. F. Hansford, C. Blondeau, and N. N. Cam. 1999. Persistence of antibodies to the Salmonella typhi capsular polysaccharide in South African school children ten years after immunization. Vaccine 17:110-113.
16. Keitel, W. A., N. L. Bond, J. M. Zahradnik, T. A. Cramton, and J. B. Robbins. 1994. Clinical and serological responses following primary and booster immunization with Salmonella typhi Vi capsular polysaccharide vaccines. Vaccine 12:195-199.
17. Klugman, K. P., I. T. Gilbertson, H. J. Koornhot, J. B. Robbins, R. Schneerson, D. Schulz, M. Cadoz, and J. Armand, and Vaccine Advisory Committee. 1987. Protective activity of Vi capsular polysaccharide vaccine against typhoid fever. Lancet ii:1165-1169.
18. Klugman, K. P., H. J. Koornhof, J. B. Robbins, and N. M. LeCam. 1996. Immunogenicity, efficacy and serological correlate of protection of Salmonella typhi Vi capsular polysaccharide vaccine three years after immunization. Vaccine 14:435-438.
19. Kossaczka, Z., S. Bystricky, D. A. Bryla, J. Shiloach, J. B. Robbins, and S. C. Szu. 1997. Synthesis and immunological properties of Vi and di-O-acetyl pectin protein conjugates with adipic acid dihydrazide as the linker. Infect. Immun. 65:2088-2093.
20. Landy, M. 1954. Studies in Vi antigen. VI. Immunization of human beings with purified Vi antigen. Am. J. Hyg. 60:52-62.
21. Lin, F.-Y., V. A. Ho, P. V. Bay, N. T. T. Thuy, D. A. Bryla, C. T. Than, H. A. Khiem, D. D. Trach, and J. B. Robbins. The epidemiology of typhoid fever Dong Thap Province, Mekong Delta Region of Vietnam. Submitted for publication.
22. Mahle W. T., and M. M. Levine. 1993. Salmonella typhi infection in children younger than five years of age. Pediatr. Infect. Dis. J. 12:627-631.
23. Murdoch, D. A., N. A. Banatvala, A. Bone, B. I. Shoismatulloev, L. R. Ward, and E. J. Threlfall. 1998. Epidemic ciprofloxacin-resistant Salmonella typhi in Tajikistan. Lancet 351:339.
24. Murphy, J. R., L. Grez, L. Schlesinger, C. Ferreccio, S. Baqar, C. Munoz, S. S. Wasserman, G. Losonsky, J. G. Olson, and M. M. Levine. 1991. Immunogenicity of Salmonella typhi Ty21a vaccine for young children. Infect. Immun. 59:291-4298.
25. Parry, C., J. Wain, N. T. Chinh, H. Vinh, and J. J. Farrar. 1998. Quinolone-resistant Salmonella typhi in Vietnam. Lancet 351:1289.
26. Plikaytis, B. D., P. F. Holder, and G. M. Carlone. 1996. Program ELISA for Windows. User's manual 12, version 1.00. Centers for Disease Control and Prevention, Atlanta, Ga.
27. Rao, P. T., and K. V. K. Rao. 1959. Typhoid fever in children. Indian J. Pediatr. 26:258-264.
28. Robbins, J. B., and R. Schneerson. 1990. Polysaccharide-protein conjugates: a new generation of vaccines. J. Infect. Dis. 161:821-832.
29. Robbins, J. B., R. Schneerson, and S. C. Szu. 1995. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J. Infect. Dis. 171:1387-1398.
30. Robbins, J. B., R. Schneerson, S. C. Szu, D. A. Bryla, F.-Y. Lin, and E. C. Gotschlich. 1998. Standardization may suffice for licensure of conjugate vaccines. Preclinical and clinical development of new vaccines. Dev. Biol. Stand. 95:161-167.
31. Rowe, B., L. R. Ward, and E. J. Threlfall. 1990. Spread of multiresistant Salmonella typhi. Lancet 336:1065.
32. Schneerson, R., O. Barrera, A. Sutton, and J. B. Robbins. 1980. Preparation, characterization and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J. Exp. Med. 152:361-376.
33. Simanjuntak, C. H., F. P. Paleologo, N. H. Punjabi, R. Darmowigoto, H. Totosudirjo, P. Haryanto, E. Suprojanto, N. D. Witham, and S. L. Hoffman. 1991. Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet 338:1055-1059.
34. Stormon, M. O., P. B. McIntyre, J. Morris, and B. Fasher. 1997. Typhoid fever in children: diagnostic and therapeutic difficulties. Pediatr. Infect. Dis. J. 16:713-714.
35. Szu, S. C., A. L. Stone, J. D. Robbins, R. Schneerson, and J. B. Robbins. 1987. Vi capsular polysaccharide-protein conjugates for prevention of typhoid fever. J. Exp. Med. 166:1510-1524.
36. Szu, S. C., D. N. Taylor, A. C. Trofa, J. D. Clements, J. Shiloach, J. C. Sadoff, D. A. Bryla, and J. B. Robbins. 1994. Laboratory and preliminary clinical characterization of Vi capsular polysaccharide-protein conjugate vaccines. Infect. Immun. 62:4440-4444.
37. World Health Organization Expert Committee on Biologic Standardization. 1993. Requirements on Vi polysaccharide for typhoid. WHO Tech. Rep. Ser. 840:14-32.
38. Yang, H. H., T. K. Wu, K. C. Hsieh, C. W. Ku, B. R. Wang, L. Y. Wang, H. F. Wang, T. S. Ding, Y. O. Yang, and W. S. Tang. Efficacy trial of Vi polysaccharide vaccine against typhoid fever in Southwestern China. Submitted for publication.